Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain

Roitbergt, F.; Amaralt, T.; Cherny, N. I.; Giuliani, R.; Latino, N. J.; Galotti, M.; Bricalli, G.; Curigliano, G.; Pentheroudakis, G.; Trapani, D.

dc.contributor.author	Amaralt, Teresa
dc.date.accessioned	2024-05-27T06:28:52Z
dc.date.available	2024-05-27T06:28:52Z
dc.date.issued	2023
dc.identifier.issn	2059-7029
dc.identifier.uri	http://hdl.handle.net/10900/153660
dc.language.iso	en	de_DE
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.esmoop.2023.101617	de_DE
dc.subject.ddc	610	de_DE
dc.title	Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_01291
utue.personen.roh	Roitbergt, F.
utue.personen.roh	Amaralt, T.
utue.personen.roh	Cherny, N. I.
utue.personen.roh	Giuliani, R.
utue.personen.roh	Latino, N. J.
utue.personen.roh	Galotti, M.
utue.personen.roh	Bricalli, G.
utue.personen.roh	Curigliano, G.
utue.personen.roh	Pentheroudakis, G.
utue.personen.roh	Trapani, D.
dcterms.isPartOf.ZSTitelID	Esmo Open	de_DE
dcterms.isPartOf.ZS-Issue	Article 101617	de_DE
dcterms.isPartOf.ZS-Volume	8 (5)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE